Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 11, 2002, Pages 77-85

  Tan, Antoinette R ^a   Swain, Sandra M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE; DOCETAXEL; FLAVOPIRIDOL; PACLITAXEL;

ANGIOGENESIS; ANIMAL MODEL; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; ENZYME INHIBITION; ENZYME REGULATION; FATIGUE; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; LUNG CANCER; MAXIMUM TOLERATED DOSE; META ANALYSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0036318722     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70130-9     Document Type: Conference Paper

References (62)

1. The hallmarks of cancer
2. Molecular biology of cancer: The cell cycle
3. Cyclin-dependent kinases: Engines, clocks, and microprocessors
4. CDK inhibitors: Positive and negative regulators of G1-phase progression
5. Cell cycle: Molecular targets for diagnosis and therapy: Tumor suppressor genes and cell cycle progression in cancer
6. Expression and amplification of cyclin genes in human breast cancer
7. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer
8. Cyclin D1 protein expression and function in human breast cancer
9. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
10. Specific protection against breast cancers by cyclin D1 ablation
11. Preferential loss of expression of p16 (INK4a) rather than p19 (ARF) in breast cancer
12. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer
13. Flavopiridol (L86-8275; NSC 649890), a new kinase inhibitor for tumor therapy
14. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target
15. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
16. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
17. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
18. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
19. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
20. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol
21. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
22. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells
23. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
24. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53
25. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia
26. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines
27. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
28. Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release
29. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells
30. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes
31. Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors
32. Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein
33. Flavopiridol binds to duplex DNA
34. Potent interaction of flavopiridol with MRP1
35. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site
36. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
37. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells
38. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
39. Docetaxel and navelbine induced apoptosis is enhanced by flavopiridol in breast cancer cells and is sequence dependent
40. Flavopiridol sensitizes breast cancer cells to gemcitabine
41. Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells
42. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
43. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
44. Phase I clinical and pharmacokinetic trial of flavopiridol
45. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea
46. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver
47. In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: Involvement of UDP-glucuronosyltransferases 1A1 and 1A9
48. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study
49. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma
50. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer
51. Phase II trial of flavopiridol in metastatic colorectal cancer: Preliminary results
52. A phase I trial of 1 hour flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with advanced neoplasms
53. Pharmacokinetics of flavopiridol IV bolus in patients with refractory neoplasms
54. Flavopiridol for mantle cell lymphoma: Moderate activity and frequent disease stabilization
55. Phase I trial of sequential paclitaxel and the cyclin-dependent kinase inhibitor flavopiridol
56. A phase IB clinical trial of the sequence dependent combination of paclitaxel and cisplatin with the cyclin dependent kinase inhibitor flavopiridol in patients with advanced solid tumors
57. Mechanisms of action of flavopiridol
58. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
59. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
60. Inhibition of the epidermal growth factor receptor (EGFR) by OSI-774, a specific EGFR inhibitor in malignant and normal tissues of cancer patients
61. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial